CONTACT US

Email.  info@prilenia.com

Tel.  +972-77-5558482

PUBLICATIONS

MEDIA

PUBLICATIONS

 

  • 2019 Sep
    Pridopidine Protects Neurons from Mutant-Huntingtin Toxicity via the Sigma-1 Receptor.
    Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA.
    Neurobiology disease

    Link: https://www.ncbi.nlm.nih.gov/pubmed/31108174
     

  • 2019 May 16
    Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease
    Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA.Frontiers in Cellular Neuroscience
    Link: https://www.ncbi.nlm.nih.gov/pubmed/31156395
     

  • 2019 Mar 1
    Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model
    Ariel Ionescu, Tal Gradus, Topaz Altman, Roy Maimon, Noi Saraf Avraham, Michal Geva, Michael Hayden, Eran Perlson.
    Cell Death & Disease

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30824685

  • 2019 Feb 12
    Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
    Veronica Francardo, Michal Geva, Francesco Bez, Quentin Denis, Lilach Steiner, Michael R. Hayden, M. Angela Cenci.
    Neurotherapeutics
    Link: https://www.ncbi.nlm.nih.gov/pubmed/30756361

  • 2018 Dec 27
    Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.
    Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, Hayden M, Bezprozvanny I.
    Neurobiology Disease

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30594810

  • 2018 Dec 21
    Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.
    Movement Disorder Societ

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30575996

  • 2018 May 21
    Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
    Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.
    Molecular Neurodegeneration

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29783994 

  • 2017 Dec 7
    Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
    Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.
    Journal of Clinical Investigation

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29212949 

  • 2017 Jan
    The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I.
    Neurobiol Disease 
    Link: https://www.ncbi.nlm.nih.gov/pubmed/27818324
     

  • 2016 Sep 15
    Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
    Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.
    Human molecular genetics
    Link: https://www.ncbi.nlm.nih.gov/pubmed/27466197
     

 

PRESS RELEASE

18 
September

2019 

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General